8648095

Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.

Celgene sued Cipla Limited for ANDA patent infringement in D.N.J., asserting 8,648,095. Terminated 2020-06-08 after settlement/dismissal.

Celgene sued Lotus Pharmaceutical and Alvogen Pine Brook for ANDA patent infringement in D.N.J. Consent judgment entered 2019-03-29 named 8,648,095 among patents-in-suit, dismissed with prejudice and enjoined Lotus ANDA No. 210480.

Celgene sued Hikma Pharmaceuticals USA for ANDA patent infringement in D.N.J., asserting 8,648,095 among other patents. Closed 2022-01-13 after settlement.

Celgene sued Hetero entities for ANDA patent infringement in D.N.J. This follow-on to Celgene v. Hetero (2:18-cv-17463) is linked to 8,648,095; consent judgment entered 2021-09-27 with marketing injunction and confidential terms.

Patent infringement action involving ANDA No. 209348; complaint expressly alleged infringement of the '800, '217, '569, '498, '095, '621 and '622 patents. Settled September 17, 2020 with volume-limited license from September 1, 2022 and unlimited from January 31, 2026.

Antitrust/pay-for-delay litigation challenging Revlimid generic settlements. Patents cited include the Revlimid patent family; on September 29, 2026, the court denied motions to dismiss, finding a plausible pay-for-delay agreement between Celgene and Natco.

Antitrust action against Celgene concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.